328 related articles for article (PubMed ID: 15647651)
61. Randomised controlled trial of pantoprazole versus ranitidine for the treatment of uninvestigated heartburn in primary care.
Talley NJ; Moore MG; Sprogis A; Katelaris P
Med J Aust; 2002 Oct; 177(8):423-7. PubMed ID: 12381251
[TBL] [Abstract][Full Text] [Related]
62. Review of esomeprazole in the treatment of acid disorders.
Johnson DA
Expert Opin Pharmacother; 2003 Feb; 4(2):253-64. PubMed ID: 12562316
[TBL] [Abstract][Full Text] [Related]
63. Effects of pantoprazole, a novel H+/K+-ATPase inhibitor, on duodenal ulcerogenic and healing responses in rats: a comparative study with omeprazole and lansoprazole.
Takeuchi K; Konaka A; Nishijima M; Kato S; Yasuhiro T
J Gastroenterol Hepatol; 1999 Mar; 14(3):251-7. PubMed ID: 10197495
[TBL] [Abstract][Full Text] [Related]
64. Cost effectiveness of proton pump inhibitors in gastro-oesophageal reflux disease without oesophagitis: comparison of on-demand esomeprazole with conventional omeprazole strategies.
Wahlqvist P; Junghard O; Higgins A; Green J
Pharmacoeconomics; 2002; 20(4):267-77. PubMed ID: 11950383
[TBL] [Abstract][Full Text] [Related]
65. Gastro-oesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors.
Katz PO; Anderson C; Khoury R; Castell DO
Aliment Pharmacol Ther; 1998 Dec; 12(12):1231-4. PubMed ID: 9882031
[TBL] [Abstract][Full Text] [Related]
66. Improving health-related quality of life in gastro-oesophageal reflux disease.
Shaw MJ; Crawley JA
Drugs; 2003; 63(21):2307-16. PubMed ID: 14524732
[TBL] [Abstract][Full Text] [Related]
67. Review article: long-term use of proton pump inhibitors in GORD--help or hindrance?
Tytgat GN
Aliment Pharmacol Ther; 2001 Sep; 15 Suppl 2():6-9. PubMed ID: 11556874
[TBL] [Abstract][Full Text] [Related]
68. Clinical response (remission of symptoms) in erosive and non-erosive gastro-oesophageal reflux disease.
Domínguez-Muñoz JE; Sobrino M
Drugs; 2005; 65 Suppl 1():43-50. PubMed ID: 16335857
[TBL] [Abstract][Full Text] [Related]
69. Therapeutic choices in reflux disease: defining the criteria for selecting a proton pump inhibitor.
Freston JW
Am J Med; 2004 Sep; 117 Suppl 5A():14S-22S. PubMed ID: 15478848
[TBL] [Abstract][Full Text] [Related]
70. Proton pump inhibitors: an update.
Vanderhoff BT; Tahboub RM
Am Fam Physician; 2002 Jul; 66(2):273-80. PubMed ID: 12152963
[TBL] [Abstract][Full Text] [Related]
71. Pantoprazole for sleepiness associated with acid reflux and obstructive sleep disordered breathing.
Steward DL
Laryngoscope; 2004 Sep; 114(9):1525-8. PubMed ID: 15475774
[TBL] [Abstract][Full Text] [Related]
72. No clinical benefit of adding cisapride to pantoprazole for treatment of gastro-oesophageal reflux disease.
van Rensburg CJ; Bardhan KD
Eur J Gastroenterol Hepatol; 2001 Aug; 13(8):909-14. PubMed ID: 11507354
[TBL] [Abstract][Full Text] [Related]
73. Pantoprazole 20 mg is effective for relief of symptoms and healing of lesions in mild reflux oesophagitis.
Dettmer A; Vogt R; Sielaff F; Lühmann R; Schneider A; Fischer R
Aliment Pharmacol Ther; 1998 Sep; 12(9):865-72. PubMed ID: 9768529
[TBL] [Abstract][Full Text] [Related]
74. An evaluation of the clinical implications of acid breakthrough in patients on proton pump inhibitor therapy.
Nzeako UC; Murray JA
Aliment Pharmacol Ther; 2002 Jul; 16(7):1309-16. PubMed ID: 12144581
[TBL] [Abstract][Full Text] [Related]
75. High-dose proton-pump inhibitors as a diagnostic test of gastro-oesophageal reflux disease in endoscopic-negative patients.
Juul-Hansen P; Rydning A; Jacobsen CD; Hansen T
Scand J Gastroenterol; 2001 Aug; 36(8):806-10. PubMed ID: 11495074
[TBL] [Abstract][Full Text] [Related]
76. Managing gastro-oesophageal reflux disease in children.
Cezard JP
Digestion; 2004; 69 Suppl 1():3-8. PubMed ID: 15001829
[TBL] [Abstract][Full Text] [Related]
77. Helicobacter pylori infection in patients with erosive esophagitis is associated with rapid heartburn relief and lack of relapse after treatment with pantoprazole.
Calleja JL; Suarez M; De Tejada AH; Navarro A;
Dig Dis Sci; 2005 Mar; 50(3):432-9. PubMed ID: 15810621
[TBL] [Abstract][Full Text] [Related]
78. Pantoprazole: from drug metabolism to clinical relevance.
Bardou M; Martin J
Expert Opin Drug Metab Toxicol; 2008 Apr; 4(4):471-83. PubMed ID: 18433349
[TBL] [Abstract][Full Text] [Related]
79. Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs.
Meyer UA
Eur J Gastroenterol Hepatol; 1996 Oct; 8 Suppl 1():S21-5. PubMed ID: 8930576
[TBL] [Abstract][Full Text] [Related]
80. Novel measurement of rapid treatment success with ReQuest: first and sustained symptom relief as outcome parameters in patients with endoscopy-negative GERD receiving 20 mg pantoprazole or 20 mg esomeprazole.
Mönnikes H; Pfaffenberger B; Gatz G; Hein J; Bardhan KD
Digestion; 2005; 71(3):152-8. PubMed ID: 15870503
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
